Antiviral Regimens for the Patients with Chronic Hepatitis C Virus Complicated with Cirrhosis / 中国药师

ABSTRACT

The efficacy of patients infected with hepatitis C virus complicated with cirrhosis is not promising after treated with present standard therapy. With more and more new drugs against hepatitis C virus, many new regimens for the patients with chronic hepatitis C virus complicated with cirrhosis have come forth. Because the adverse reactions of the first generation HCV protease inhibi-tors telaprevir and boceprevir are severe, they are not recommended to be used in the patients with chronic hepatitis C virus complicated with cirrhosis. The other drugs, such as simeprevir, sofosbuvir and ledipasvir show good efficacy in the patients with chronic hepatitis C virus complicated with cirrhosis, however, the sustained virological response ( SVR) in the patients with chronic hepatitis C virus complicated with cirrhosis is lower than that in the patients with chronic hepatitis C virus without cirrhosis. Therefore, the regimens should be optimized in the future to narrow the gap in SVR.